Positive Phase 1b Results Demonstrate Precise Timed Delivery for Contera Pharma’s CP-012 Using BDD’s OralogiK™ Technology
Glasgow, UK – September 17th, 2025
BDD Pharma Ltd., a UK-based leader in oral drug delivery and early-phase clinical research, is today delighted to share that positive topline results have been reported by friends and partners Contera Pharma from their recent Phase 1b pharmacoscintigraphic study . The study evaluated Contera’s CP-012 product, a delayed pulsatile levodopa/carbidopa tablet built on BDD’s proprietary OralogiK™ timed-release platform. The single-centre, open-label, crossover study –which was conducted at BDD’s integrated development and clinical site in Glasgow , supports CP-012’s design to target nocturnal immobility and early-morning akinesia in people living with Parkinson’s disease.
CP-012 was safe and well tolerated and combined pharmacokinetic and scintigraphic data demonstrated delayed, pulsatile release of levodopa aligned to the early-morning window, when symptoms are typically most challenging.
Dr Lyn Corry, Research Medical Director at BDD and PI for the study said: ” I was delighted to act as PI for this study which demonstrated successful delayed, overnight delivery of carbidopa/levodopa to people living with Parkinson’s disease, with no detectable change in safety and tolerability. CP-012 has the potential to significantly improve symptoms and quality of life for those with nocturnal symptoms and morning akinesia. I would like to thank all of our volunteers who participated in the study, our partners at Neuroclin for helping with recruitment, and the clinical team at BDD’s Phase I clinical trial unit.”
Study overview
The exploratory Phase 1b pharmacoscintigraphic study evaluated two delayed, pulsatile CP-012 formulations in up to 15 participants living with Parkinson’s disease. The primary objective was to characterise levodopa/carbidopa absorption (PK) and correlate that with the scintigraphic time and site of release. The study was delivered in collaboration with Contera Pharma at BDD’s Glasgow clinical unit, leveraging BDD’s on-site gamma camera imaging.
Dr Carol Thomson, Chief Executive Officer at BDD, added: “This study not only validates the programmability of OralogiK for complex release profiles, but also showcases the strength of BDD’s Lean Clinical Development™ pathway Bringing together formulation, technology and on-site Phase 1 execution, to generate fast, decision-ready evidence for timed-release products. We congratulate the Contera team and look forward to the next stage of development.”
About OralogiK™
OralogiK™ is BDD’s proprietary, programmable timed-release platform for oral tablets. It enables single or multiple precisely timed pulses and delayed-onset profiles from a single dose, supporting target windows such as early-morning symptom control or multi-pulse daytime coverage. OralogiK has been validated in multiple clinical scintigraphy studies at BDD’s site.
About CP-012 & Contera Pharma
CP-012 is an investigational, delayed-pulsatile levodopa/carbidopa tablet developed by Contera Pharma A/S to address nocturnal immobility and early-morning akinesia in people living with Parkinson’s disease. Contera Pharma holds a license to BDD’s OralogiK™ technology for the CP-012 programme.
About BDD Pharma Ltd.
BDD Pharma Ltd. is a UK-based CRO/CDMO specialising in oral drug delivery, formulation development, GMP manufacturing, gamma scintigraphy, and early-phase clinical trials. BDD’s Lean Clinical Development™ pathway integrates formulation prototyping and on-site Phase 1 evaluation to compress timelines from product concept to Phase I clinical data. Proprietary platforms such as OralogiK™ enable differentiated release profiles and rapid in-vivo validation at BDD’s MHRA-accredited Glasgow facility.
For more information, visit www.bddpharma.com.
ENDS
Media Contact:
BDD Pharma Ltd.
Email: enquiries@bddpharma.com | Tel: +44 (0)141 552 8791